S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)

Bibliografski detalji
Glavni autori:	M. D’Agostino, S. Bringhen, R. Ria, F. Ciceri, A. P. Falcone, M. Michieli, M. Grasso, F. Pane, M. Quaresima, F. Cattel, M. Mirabile, F. Fioritoni, M. T. Petrucci, V. Cotugno, A. Capra, S. Pezzatti, M. L. Mosca Siez, M. Cantonetti, G. Margiotta Casaluci, P. Bertazzoni, R. Floris, M. Offidani, G. Pietrantuono, A. Evangelista, M. Boccadoro, A. Larocca
Format:	Članak
Jezik:	English
Izdano:	Wiley 2022-06-01
Serija:	HemaSphere
Online pristup:	http://journals.lww.com/10.1097/01.HS9.0000844092.71570.04

Slični predmeti

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
od: A. Larocca, i dr.
Izdano: (2023-05-01)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
od: Mattia D’agostino, i dr.
Izdano: (2023-08-01)

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
od: María-Victoria Mateos, i dr.
Izdano: (2014-06-01)

Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation
od: R. Veelken, i dr.
Izdano: (2024-09-01)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
od: Alessandra Larocca, i dr.
Izdano: (2020-04-01)

Cutaneous toxicity following intra-arterial chemotherapy with melphalan for uveal melanoma: A case report
od: Arthur Sampaio Zupelli, i dr.
Izdano: (2024-09-01)

P12 HEALTH-RELATED QUALITY OF LIFE IN FRAIL AND INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DOSE-ADJUSTED MELPHALAN-PREDNISONE-BORTEZOMIB (MPV)
od: M.R. Seefat, i dr.
Izdano: (2023-05-01)

Cooperative Localization and Time Synchronization Based on M-VMP Method
od: Zhongliang Deng, i dr.
Izdano: (2020-11-01)

Intravitreal Melphalan Chemotherapy for Vitreous Seeds in Retinoblastoma
od: Yacoub A. Yousef, i dr.
Izdano: (2020-01-01)

Intravitreal and Subconjunctival Melphalan for Retinoblastoma in Transgenic Mice
od: Nisha V. Shah, i dr.
Izdano: (2014-01-01)

Cost-effectiveness analysis of daratumumab plus bortezomib, melphalan and prednisone versus bortezomib, melphalan and prednisone in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation
od: Dan Xie, i dr.
Izdano: (2025-02-01)

Encephalopathy complicating high-dose melphalan.
od: Schuh, A, i dr.
Izdano: (1999)

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation
od: Amalia Domingo-González, i dr.
Izdano: (2024-09-01)

Repeated use of hybrid isolated chemoperfusion with melphalan in non-resectable liver malignancy
od: A. I. Babich, i dr.
Izdano: (2024-03-01)

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
od: Antonio Palumbo, i dr.
Izdano: (2010-07-01)

VMP1: a multifaceted regulator of cellular homeostasis with implications in disease pathology
od: Jia Tong, i dr.
Izdano: (2024-07-01)

Loss of hepatic VMP1 trapped VLDL in the bilayer of endoplasmic reticulum membrane
od: Hong-Min Ni, i dr.
Izdano: (2023-06-01)

Ultrastructural changes in the rabbit retina after various one-time doses of intravitreal melphalan
od: N.F. Bobrova, i dr.
Izdano: (2020-08-01)

Isolated chemohyperthermal perfusion of the liver with melphalan in the treatment of unresectable liver metastases with uveal melanoma
od: A. D. Kaprin, i dr.
Izdano: (2021-12-01)

Clinical and ultrastructural changes in the rabbit retina at various doses and numbers of intravitreal melphalan injections
od: N. F. Bobrova
Izdano: (2022-12-01)

Clinical and pathomorphological changes in the rabbit retina after an injection of various doses of the cytostatic melphalan
od: N. F. Bobrova, i dr.
Izdano: (2023-11-01)

Association of homelessness and diet on the gut microbiome: a United States-Veteran Microbiome Project (US-VMP) study
od: Andrew J. Hoisington, i dr.
Izdano: (2024-01-01)

Candidate Members of the VMP/EMP Disk System of the Galaxy from the SkyMapper and SAGES Surveys
od: Jihye Hong, i dr.
Izdano: (2024-01-01)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
od: M. Offidani, i dr.
Izdano: (2023-05-01)

PB2178: OUTCOMES OF REDUCED DOSE TEAM (THIOTEPA, ETOPOSIDE, CYTARABINE, MELPHALAN) PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION FOR HODGKIN AND NON-HODGKIN LYMPHOMA: A MONOCENTRIC EXPERIENCE
od: S. Di Folca, i dr.
Izdano: (2022-06-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
od: S. S. Bessmeltsev, i dr.
Izdano: (2022-11-01)

VMP-ER: An Efficient Virtual Machine Placement Algorithm for Energy and Resources Optimization in Cloud Data Center
od: Hasanein D. Rjeib, i dr.
Izdano: (2024-07-01)

ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma
od: Sung-Soo Park, i dr.
Izdano: (2023-05-01)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
od: Francesca Bonello, i dr.
Izdano: (2020-12-01)

Biogenic calcium carbonate as evidence for life
od: S. Ronca, i dr.
Izdano: (2023-10-01)

P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY/RELAPSED AML PATIENTS
od: S. Chen, i dr.
Izdano: (2022-06-01)

Unresectable Hepatic Metastasis of Uveal Melanoma: Hepatic Chemosaturation with High-Dose Melphalan—Long-Term Overall Survival Negatively Correlates with Tumor Burden
od: R. Brüning, i dr.
Izdano: (2020-01-01)

PB2193: IS HYPERHYDRATION NECESSARY FOR HIGH DOSE MELPHALAN CONDITIONING REGIMEN IN AUTOLOGOUS HAEMATOPOIETIC STEM CELL TRANSPLANTATION?
od: M. Mora Argumánez, i dr.
Izdano: (2022-06-01)

Meta-analysis of the Vmp-like sequences of Lyme disease Borrelia: evidence for the evolution of an elaborate antigenic variation system
od: Steven J. Norris, i dr.
Izdano: (2024-10-01)

Quality of Life Assessment in Patients with Knee Osteoarthritis
od: A. Feki, i dr.
Izdano: (2024-04-01)

Effectiveness of Mindfulness Training on Emotion Regulation and Quality of Life of Addict’s Wife
od: f a, i dr.
Izdano: (2016-06-01)

Intravitreal Melphalan for Vitreous Seeds: Initial Experience in China
od: Xunda Ji, i dr.
Izdano: (2016-01-01)

Fatigue, fracture, and life prediction criteria for composite materials in magnets
od: Wong, F.M.
Izdano: (2015)

Fuzzy Inference System for Predicting Functional Service Life of Concrete Pavements in Airports
od: A. J. Prieto, i dr.
Izdano: (2022-11-01)

Philosophy for life /
od: Lavery, M. A.
Izdano: (2007)